Summary Tumorigenesis is related to the dysregulation of cell growth or cell death pathways. Hence, elucidation of the mechanisms involved in the modulation of pro-or anti-apoptotic proteins is important in furthering understanding of breast cancer aetiology and may aid in designing prevention and treatment strategies. In the present study, we examined the role of 17β-oestradiol on the regulation of apoptosis in the breast cancer cell line MCF-7. Using multi-probe RNAase protection assays, we found changes in the mRNA levels of several Bcl-2 family proteins upon treatment of MCF-7 cells with 17β-oestradiol. Unexpectedly, we found a paradoxical effects of 17β-oestradiol on two anti-apoptotic proteins Bcl-2 and Bcl-x. Treatment with 17β-oestradiol resulted in up-regulation of Bcl-2 mRNA and protein, but down-regulated Bcl-x(L) mRNA and protein. The effect of 17β-oestradiol on Bcl-x(L) occurred at concentration-dependent fashion. The effect was specific to 17β-oestradiol since other steroid hormones exert no effect on Bcl-x(L). Tamoxifen, an anti-oestrogen, blocked the down-regulation of Bcl-x(L) by 17β-oestradiol demonstrating this effect is oestrogen receptor-dependent. We speculate that different members of the Bcl-2 family proteins may be regulated through different pathway and these pathways may be modulated by 17β-oestradiol.
Apoptosis is a physiological process that is crucial to the growth and development of multicellular organisms. Its dysregulation has been linked to tumorigenesis (Mikulski, 1994; Wyllie, 1997) . Several proteins have been identified to be components of the complex apoptosis machinery. Bcl-2, which is associated with the t(14;18) chromosomal breakpoint that occurs in follicular lymphoma, was the first protein identified to possess antiapoptotic properties (Tsujimoto et al, 1985) . Subsequently, additional proteins that share structural homology with Bcl-2 have been identified and characterized (Reed, 1994; McDonnell et al, 1996; Kroemer, 1997) . These proteins, categorized as Bcl-2 family proteins, have been widely studied in programmed cell death and appear to possess either anti-or pro-apoptotic properties (Reed, 1994; McDonnell et al, 1996; Kroemer, 1997) . In addition to the Bcl-2 family proteins, activation of the tumour necrosis factor (TNF) receptor family proteins by their respective ligands can trigger apoptosis (Wallach et al, 1997; Ashkenazi and Dixit, 1998) . Initiation of apoptosis occur downstream of the ligand-receptor interaction through proteolytic cascade that involve caspases (Wallach et al, 1997; Ashkenazi and Dixit, 1998) . Moreover, interaction between the two families of proteins mentioned above may also occur. It has been shown that anti-apoptotic proteins Bcl-2 and Bcl-x can inhibit various TNF receptor-mediated apoptotic events (Hermann et al, 1997; Srinivasan et al, 1998) . Hence, coordination of various components of different apoptosis pathways may be necessary to ensure final execution of pro-or antiapoptotic signals.
Perturbation of Bcl-2 family proteins, and consequently apoptosis, may be important in mammary carcinogenesis. Overexpression of the long form of the Bcl-x protein has been observed in invasive breast cancer, and using Bcl-x protein expression as a prognostic tool for monitoring breast cancer progression has been suggested (Olopade et al, 1997) . In addition, others have shown that expression of Bax in normal breast tissues is significantly higher than in malignant breast tissues (Bargou et al, 1995) . Exposure to oestradiol has been found to be associated with increased risk in development of mammary tumour (Fishman et al, 1995) . Given the involvement of Bcl-2 family proteins in tumorigenesis (Reed, 1994; McDonnell et al, 1996; Kroemer, 1997) , modulation of the Bcl-2 family anti-or pro-apoptotic proteins by oestradiol may play a critical role in the mammary carcinogenesis. Recent work has indicated a potential role for 17β-oestradiol in modulation of Bcl-2 family proteins, such as the anti-apoptotic protein Bcl-2 (Wang and Phang, 1995; Huang et al, 1997) and proapoptotic protein Bak (Leung et al, 1998) . These results appear to correlate with the anti-apoptotic property of oestradiol (Kyprianou et al, 1991) . However, it remains unclear if various Bcl-2 family proteins may be coordinately regulated by oestradiol. Given that therapeutic and prevention strategies utilizing anti-oestrogens have been actively explored (Jordan, 1998) , a better understanding of the role of oestradiol in modulating the Bcl-2 family proteinrelated apoptosis pathways may benefit development of breast cancer therapeutic and prevention strategies. To address the possible complex interaction of oestradiol with apoptosis pathways and taking into consideration that oestradiol, functioning through oestrogen receptor, can serve as transcriptional activator, we (1) examined the effects of oestradiol on Bcl-2 family proteins at both the message and protein levels and (2) asked whether various pro-or anti-apoptotic proteins can be regulated by oestradiol in a coordinated fashion. Our results indicate that (1) Bcl-2 Paradoxical regulation of Bcl-2 family proteins by 17β-oestradiol in human breast cancer cells MCF-7 family proteins may be di fferentially regulated by 1 7 β-oestradiol and (2) 1 7 β-oestradiol exert paradoxical e ffects on the antiapoptotic proteins Bcl-2 and Bcl-x(L).
MATERIALS AND METHODS

Chemicals
Progesterone, tamoxifen, dihydrotestosterone and 1 7 β-oestradiol were purchased from Sigma (St Louis, MO, USA). Recombinant human insulin-like growth facto r-I (IGF-I) and recombinant human epidermal growth factor (EGF) were obtained from Promega (Madison, WI, USA). All other chemicals were from the best sources available.
Cell culture
MCF-7 cells were cultured as previously described ( Wang and Phang, 1995) . Briefl y, 1 week before initiation of the experiment, cells were switched to phenol red-free RPMI-1640 (Biofluids, Rockville, MD, USA) supplemented with 5% charcoal dextrantreated fetal bovine serum (CDS) (Hyclone Laboratories Inc., Logan, U T, USA), 2 m M glutamine, 100 units ml -1 penicillin, 10 0 µg ml -1 streptomycin, 1 n M insulin and 2 ng ml -1 hydrocortisone for 3 days. Subsequentl y, cells were switched to media without insulin and hydrocortisone, and 1 day before treatment cells were trypsinized and plated in phenol red-free RPMI-1640 containing 2 m M glutamine, 100 units ml -1 penicillin, 10 0µg ml -1 streptomycin and 5% CDS.
Determination of cell number and apoptosis for MCF-7 cells
We used DNA fragmentation as the criteria for apoptotic cell death. DNA fragmentation was measured using the cell death enzyme-linked immunosorbent assay (ELISA) (Boehringe r, Indianapolis, IN, USA). Cells ( 5 × 10 4 cell) were plated in each well of 24-well plates. After treatment, the cells were washed once with phosphate-bu ffered saline and 0. 5 ml lysis bu ffer was added. After a 30-min incubation the supernatant was recovered and assayed for DNA fragments according to manufacture r's protocol. Additional plates identically treated as above were analysed for cell number using the sulphorhodamine assay ( Wang and Phang, 1995) . The OD 405 obtained from the DNA fragmentation assay was then normalized for cell number and the results are expressed relative to untreated control.
Total RNA isolation, multi-probe RNAase protection assay and RT-PCR MCF-7 cells were grown in 6-well Costar plates ( 2 × 10 6 cells well -1 ), and total RNA was isolated as described previously ( Wang and Phang, 1995) . Multi-probe RNAase protection assay for Bcl-2 family and TNF receptor family protein were performed using the RiboQuant RNase protection assay (Pharmingen, San Diego, CA, USA) according to the manufacture r's protocol. The template set used were hAPO-2 for Bcl-2 family proteins. The protected fragments were visualized by autoradiography and quantitated using a phosphoimager (BioRad GS-360) respectivel y. Phosphoimager readings were normalized for glyceraldehyde 3-phosphate dehydrogenase (GAPDH) content. Determination of Bcl-x mRNA levels using semiquantitative reverse transcription polymerase chain reaction ( RT-PCR) were performed as follows. First-strand synthesis was performed using a RT-PCR kit from Stratagene (CA, USA) using 0.1-0. 5 µg of total RNA. Subsequent cDNA amplification was performed using the following primers for Bcl-x: 5′-AAT GTC TCA GAG CAA CCG GGA GCT G-3 ′ (forward primer) and 5 ′-TCA TTT CCT ACT GAA GAG TGA GCC CA-3 ′ (reverse primer), primers for GAPDH were obtained from Clontech (CA, USA). The conditions for PCR were as previously described ( Wang and Phang, 1995) except 20 cycles were performed in the presence of 1 0 µCi of [α-P 32 ] dATP (300 0 Ci mmol -1 ) per reaction. The linearity of the amplification cycles was confirmed by separate experiments. The PCR products were then separated on a 2% agarose gel. The gel was dried and exposed to a Kodak X-OM AT AR film or phosphoimager screen (BioRad, Richmond, CA, USA). The amplified cDNA fragments were visualized by autoradiography and quantitated using a phosphoimager (BioRad GS-360) respectivel y. Phosphoimager readings were normalized for GAPDH content. The Bcl-x primers were designed to amplify both long (70 2 bp) and short forms (48 8 bp), but the short form was not detectable under the conditions used.
Immunodetection of Bcl-2 family proteins levels
MCF-7 cells were plated in 100-mm dishes at 5 × 10 6 cells dish
and treatments were begun 2 4 h after plating. Treated cells were harvested by washing once with phosphate-bu ffered saline (PBS), pH 7.4, and scraping from the dish into 0.
5 ml bu ffer (PBS, pH 7.4, 1% NP40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulphate (SDS) supplemented with protease inhibitors (10 0 µg ml -1 phenylmethyl sulphonyl fluoride, 1 µg ml -1 aprotinin, 1 µg ml -1 leupeptin, 1 m M EDTA, 1 µg ml -1 pepstatin). Cells were then lysed by sonication on ice ( Tekmar Sonic Disrupto r, 30% powe r, 3 0 s) to obtain cell lysate for Western blotting. Protein concentration of the cell lysate was determined by the Dc protein assay (Bio-Rad, Richmond, CA, USA). Aliquots of cell lysate containing 15-2 5µg of protein were separated on 10% SDS polyacrylamide gel electrophoresis (SDS-PAGE) (Novex, San Diego, CA, USA) and electro-transferred to polyvinyldifluoride membrane (Millipore, Bedford, MA, USA). The membranes were then probed with antibody against Bcl-2 (Dako, Carpinteria, CA, USA), Bcl-x (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), Bak (Upstate Biochemicals, Lake Placid, N Y, USA) or Bax (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) and visualized with the enhanced chemiluminescence method (Pierce, IL, USA).
RESULTS
Effects of 17β-oestradiol on cell number and apoptosis in human breast cancer cell line MCF-7
Treatment of oestrogen receptor (ER)-positive MCF-7 cell with oestradiol can result in increased cell numbers. As shown in Figure  1A , MCF-7 cell cultured in presence of 10 -10 M 17β-oestradiol for 48 h resulted in significantly higher cell number than the untreated control. This e ffect of 1 7
β-oestradiol on cell number homeostasis appeared exerted in part through a decrease in apoptosis. The relative apoptotic index for cells cultured in presence of oestradiol were significantly lower than cells cultured in absence of 17β-oestradiol ( Figure 1B ).
Effects of 17β-oestradiol on Bcl-2 family proteins' mRNA expression
To further understand the mechanism underlying the effect of oestradiol on apoptosis, we began by examining the effect of 17β-oestradiol on the Bcl-2 family proteins, essential components of apoptosis pathways. Given that 17β-oestradiol can exert its effect through interaction with ER and serve as transcriptional factor, we initially examined the effects of oestradiol on the mRNA levels of the Bcl-2 family proteins. Taking advantage of a multi-probe RNAase protection assay, we compared mRNA expression of Bcl-2 family proteins in cells cultured in presence and absence of 17β-oestradiol (Figure 2 ). After normalization to GAPDH, we found several differences between cells cultured in the presence or absence of 17β-oestradiol. Unexpectedly we found treatment of cells with 17β-oestradiol led to a decrease in the antiapoptotic protein Bcl-x mRNA levels ( Figure 2A ). Treatment with 17β-oestradiol also leads to alteration in another Bcl-2 family proteins, Bak, which we have previously reported (Leung et al, 1998) .
Concentration-dependent effects of 17β-oestradiol on Bcl-x mRNA expression
Down-regulation of the anti-apoptotic protein Bcl-x mRNA, as demonstrated above using multi-probe RNAase protection assay, appears to contradict the anti-apoptotic property of oestradiol. Therefore, to further confirm that treatment with 17β-oestradiol indeed led to decreased levels of Bcl-x mRNA, we used a semiquantitative RT-PCR as an alternative method to assess this 
Figure 3
Concentration-dependent effects of 17β-oestradiol on Bcl-x(L) mRNA levels. MCF-7 cells were treated with the indicated concentrations of 17β-oestradiol for 120 h. Total RNA was isolated, and the Bcl-x(L) mRNA level was determined as described in Materials and Methods. *Represents value (from three separate treatments) significantly different from that of control (P < 0.05, ANOVA) alteration in Bcl-x message. Consistent with the multi-probe RNAase protection assay, Bcl-x mRNA as assessed by semiquantitative RT-PCR was significantly less in cells cultured in the presence of 17β-oestradiol than in untreated controls (Figure 3 ). In addition, the effect of 17β-oestradiol on Bcl-x mRNA levels appeared to be concentration-dependent. Under these RT-PCR conditions only the long form-Bcl-x(L), but not the short formBcl-x(S) of Bcl-x, mRNA were detected.
Comparison of the effects of 17β-oestradiol on Bcl-x(L) to other Bcl-2 family proteins
Having established an effect of oestradiol on Bcl-x(L) mRNA, we further compared the effects of 17β-oestradiol on Bcl-x to several other Bcl-2 family proteins at the protein levels using immunodetection. As illustrated in Figure 4 , Bcl-x(L) protein increased in a time-dependent fashion. Treatment with 17β-oestradiol suppressed the time-dependent increase in Bcl-x protein, and the effects can be observed after 24 h. In contrast, treatment of MCF-7 cells with 10 -10 M 17β-oestradiol resulted in a time-dependent increase in expression of the anti-apoptotic protein Bcl-2. The effects of 17β-oestradiol on Bcl-2 can also be seen after 24-h treatment. Treatment with 17β-oestradiol resulted in suppression of the increase in the pro-apoptotic protein Bak. The time course for oestradiol's effect on Bak appeared to be different from that of Bcl-2 or Bcl-x. Significant changes in Bak expression were detected only after 72 h treatment with 17β-oestradiol. In addition, we also compared the concentration effects of 17β-oestradiol on the Bcl-2 family proteins described above. As shown in Figure 5 , the threshold of responses of anti-apoptotic protein Bcl-2, Bcl-x and pro-apoptotic proteins Bak, to 17β-oestradiol appeared to be similar. Significant changes in all three proteins can be observed at 10 -11 M 17β-oestradiol. There were no significant differences in Bax protein at any time point or treatment.
Specificity and mechanism of 17β-oestradiol's effect on Bcl-x(L) in MCF-7 cells
As we observed a difference in Bcl-x(L) levels in cells cultured in presence and absence of 17β-oestradiol, we asked whether this change was unique to 17β-oestradiol and whether this is through ER-dependent pathway. The effects of oestradiol on Bcl-x(L) was compared to that of various steroid hormones or growth factors with known biological effects on mammary cells. These factors included: 17β-oestradiol (10 -10 M), progesterone (10 -9 M), dihydrotestosterone (10 -9 M), EGF (10 ng ml -1 ), or IGF-I (10 ng ml -1
). As illustrated in Figure 6 , after a 5-day incubation, only treatment with 17β-oestradiol resulted in the suppression of Bcl-x(L), while other treatments did not alter Bcl-x(L) protein levels. The inhibitory effects of 17β-oestradiol appeared to be executed 
DISCUSSION
Oestradiol is a known risk factor in the development of mammary cancer (Fisherman et al, 1995) ; however, the mechanism by which oestradiol exerts its effect is still unclear. Given the importance of apoptosis in tumorigenesis (Mikulski, 1994; Wyllie, 1997) and recent works implicating alteration of apoptosis pathways in mammary tumorigenesis (Bargou et al, 1995; Olopade et al, 1997) , modulation of apoptosis pathways by oestradiol can be an important mechanism by which oestradiol can exert its effect on mammary carcinogenesis. It has been established, by this laboratory and others (Teixeria et al, 1995; Wang and Phang, 1995) , that oestradiol induces proliferation of human mammary tumour cells in vitro, and this effect is due in part to a decrease in apoptosis. Figure 1 confirms that treatment of oestradiol can result in both increased cell numbers and decreased apoptosis. To further understand the mechanisms underlying the effect of oestradiol on apoptosis, it would be important to examine the effect of 17β-oestradiol on the various components of apoptosis pathways. With respect to components of apoptosis pathways much attention has been focused on Bcl-2, which has been shown to have potent anti-apoptotic effects on tumour cells (Reed, 1994; McDonnell et al, 1996; Kroemer, 1997) . However, Bcl-2 is just one protein in a complex and diverse family of proteins which have been shown to have either anti-or pro-apoptotic properties (Reed, 1994; McDonnell et al, 1996; Kroemer, 1997) . In addition, apoptosis has also been shown to be regulated by another family of proteins, the TNF receptor family (Wallach et al, 1997; Ashkenazi and Dixit, 1998) . The regulation of these separate pathways and how alterations in expression of the various family members result in cell death is complicated and remains largely unclear. To elucidate the roles of oestradiol we began by investigating the effects of oestradiol on the mRNA levels of the Bcl-2 family proteins.
Interestingly, in an initial screening using a multi-probe RNAase protection assay (Figure 3) we observed that cells cultured in presence of 17β-oestradiol expressed lower levels of the anti-apoptotic protein Bcl-x mRNA than the untreated controls. Since Bcl-x has been shown to be anti-apoptotic (Hu et al, 1998; Srinivasan et al, 1998) , down-regulation of Bcl-x(L) is at odds with the antiapoptotic effect of oestradiol. Therefore, we further investigated the effect of oestradiol on Bcl-x. As shown in Figure 3 , this effect of 17β-oestradiol on Bcl-x mRNA was subsequently confirmed by semi-quantitative RT-PCR and we found that treatment with 17β-oestradiol resulted in concentration-dependent changes in Bcl-x(L) mRNA. The changes in Bcl-x(L) mRNA were reflected at the protein level. As shown in Figures 4 and 5, treatment with 17β-oestradiol also resulted in lower levels of Bcl-x(L) protein.
The effect of 17β-oestradiol appeared to be suppression of a temporal increase of Bcl-x(L) during culturing of MCF-7 cells. The level of Bcl-x(L) increased during the culturing periods (0-120 h), and the addition of 17β-oestradiol attenuated that increase. The effect of 17β-oestradiol on Bcl-x(L) is in contrast to the effects of 17β-oestradiol on another anti-apoptotic protein, Bcl-2. Treatment with 17β-oestradiol resulted in an increase in both Bcl-2 mRNA and protein levels. Treatment with 17β-oestradiol also affected the pro-apoptotic proteins Bak and Bax differently. Treatment with 17β-oestradiol resulted in downregulation of Bak, but exerted little effect on Bax, both at the mRNA and protein levels. The concentration of 17β-oestradiol that elicited an effect on the various Bcl-2 family proteins was similar. However, there appeared to be a difference in temporal changes of various Bcl-2 family proteins upon exposure to 17β-oestradiol. While changes in Bcl-2 and Bcl-x(L) occurred as early as 24 h, the effect on Bak appeared to occur after 72 h.
In order to demonstrate the specificity of 17β-oestradiol as well as the mechanism of action, we compared the effects of oestradiol to other steroid hormones and cytokines. The addition of progesterone and dihydrotestosterone did not alter Bcl-x(L) levels. Thus, the effects of 17β-oestradiol on Bcl-x(L) appeared to be specific among the steroid hormones. In addition, oestradiol is known to affect growth factors, which are believed to be responsible for part of the proliferative responses induced by oestradiol (de Cupis and Favoni, 1997) . Treatment with EGF or IGF-1 did not cause any changes in Bcl-x(L) levels. Thus, oestradiol does not appear to exert its effect on Bcl-x(L) indirectly through regulation of these growth factors. These results on Bcl-x is similar to what we have found for Bak (Leung et al, 1998) and Bcl-2 (TT Wang, unpublished observations). To determine whether the ER was necessary for oestradiol to exert its effect on Bcl-x(L), we treated cells with the anti-oestrogen tamoxifen. As shown in Figure 6 , addition of tamoxifen negated the suppressive effects exerted by 17β-oestradiol, supporting that the effect of 17β-oestradiol was mediated through ER-dependent pathways. The effects of 17β-oestradiol on the Bcl-2 family proteins may be indirect, there is no apparent consensus of an oestrogen-responsive element in the Bcl-x or the Bcl-2 promoter sequences (Grillot et al, 1997) . However, several other consensus sequences for various other transcriptional factors are present. Oestradiol may thus exert its effect indirectly through one or more of these pathways.
The present study and our previous work (Wang and Phang, 1995; Leung et al, 1998) clearly demonstrated that oestradiol coordinately regulated the expression of several within the Bcl-2 family of proteins, and this occurs in an ER-dependent manner. This supports our hypothesis that oestradiol may regulate apoptosis through its effect on Bcl-2 family proteins. However, since oestradiol inhibited apoptosis (Figure 1 ) and Bcl-x is known to possess anti-apoptotic property, the down-regulation of Bcl-x by oestradiol is difficult to interpret. However, we speculate that upregulation of Bcl-x(L) may be associated with cell survival in the absence of proliferative signals. Up-regulation of Bcl-x(L) in absence of proliferative signal may serve to insure cell survival in the absence of growth signals. In the presence of oestradiol, however, the survival pathway may have been inactivated, thus down-regulation of Bcl-x occurred. By contrast, the other antiapoptotic protein Bcl-2 may be associated with proliferative responses so that the cells can prevent apoptosis and take full advantages of proliferative signals induced by oestradiol. It is interesting, in this light, to consider a recent study which has shown that Bcl-x(L) is often over-expressed in ER-negative invasive tumours (Olopade et al, 1997) . This is consistent with the current data, which show that Bcl-x(L) expression is higher in absence of an oestradiol signal.
In summary, 17β-oestradiol exerted a differential effect on Bcl-2 family proteins in ER-positive human breast cancer cell line MCF-7. Interestingly, 17β-oestradiol appeared to exert a paradoxical effect on the anti-apoptotic protein Bcl-2 and Bcl-x(L). We proposed that different pathways may be involved in regulation of Bcl-2 family proteins, and 17β-oestradiol may exert an effect on these pathways.
